Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
62,457,444
-
Total 13F shares
-
56,712,373
-
Share change
-
+73,783
-
Total reported value
-
$945,896,121
-
Put/Call ratio
-
11%
-
Price per share
-
$16.68
-
Number of holders
-
142
-
Value change
-
-$53,252,231
-
Number of buys
-
82
-
Number of sells
-
75
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock, $0.00001 par value (PTGX) as of Q3 2023
As of 30 Sep 2023,
Protagonist Therapeutics, Inc - Common Stock, $0.00001 par value (PTGX) was held by
142 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
56,712,373 shares.
The largest 10 holders included
BVF INC/IL, FARALLON CAPITAL MANAGEMENT LLC, RTW INVESTMENTS, LP, BlackRock Inc., STATE STREET CORP, VANGUARD GROUP INC, JOHNSON & JOHNSON, Kynam Capital Management, LP, COWEN AND COMPANY, LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
142
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.